RxDoctor Payments Data

Arletty Smith, MD

Family Medicine · Orange City, FLNPI 1699777342

Payments from drug & device makers

$3,528in general payments, 2019–2025

Across 203 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$969
  • AbbVie$473
  • Abbott$470
  • Lilly USA, LLC$305
  • Amgen$271
  • Astellas Pharma US Inc$246
  • plus $793 from 17 others

What the payments were for

  • Food & beverage$3,45398%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,528 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$48,582
Medicare patients
137
Services billed
860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$111,701
JardianceEmpagliflozin66$69,031
EliquisApixaban61$61,833
TrulicityDulaglutide26$48,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$32,297
FarxigaDapagliflozin Propanediol38$29,885
MounjaroTirzepatide11$23,564
JanuviaSitagliptin Phosphate19$18,765
XareltoRivaroxaban26$17,266
MyrbetriqMirabegron22$13,904
Synjardy XrEmpagliflozin/Metformin Hcl24$12,103
Repatha SyringeEvolocumab21$11,523
Celecoxib66$8,916
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$8,363
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$969$116,209130 claims
Boehringer IngelheimJardiance, Synjardy Xr$54$81,13490 claims
Lilly USA, LLCTrulicity, Mounjaro$305$72,26737 claims
PfizerEliquis$43$61,83361 claims
GSKTrelegy Ellipta, Anoro Ellipta$97$38,76751 claims
AstraZenecaFarxiga$242$29,88538 claims
Johnson & JohnsonXarelto$16$17,26626 claims
Astellas Pharma US IncMyrbetriq$246$13,90422 claims
Sanofi-aventis U.S. LLCLantus$17$4,05019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →